A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Status:
Not yet recruiting
Trial end date:
2029-10-26
Target enrollment:
Participant gender:
Summary
This study has 2 parts.
The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or
refractory B-cell Non-Hodgkin Lymphoma.
The main aim of Part 2 is to learn if lymphomas are reduced or gone after treatment
withTAK-007 in adults with relapsed or refractory B-cell Non-Hodgkin Lymphoma or indolent
non-Hodgkin lymphoma (iNHL).
Participants will receive lymphodepleting chemotherapy for 3 days before receiving a single
injection of TAK-007. After this, participants will regularly visit the clinic for check-ups.